Limits...
Role of posaconazole in the treatment of oropharyngeal candidiasis.

Ianas V, Matthias KR, Klotz SA - Infect Drug Resist (2010)

Bottom Line: Posaconazole is the newest azole antifungal approved by the US Food and Drug Administration, and possesses a broad spectrum of activity against numerous yeasts and filamentous fungi.It is available as an oral suspension and is generally well tolerated by patients, but gastrointestinal absorption is sometimes inadequate and remains a clinical concern in treating deep-seated infections.It is used routinely and effectively for the prophylaxis of invasive fungal infections in immunosuppressed hosts and is an effective treatment of oropharyngeal candidiasis, including azole-resistant disease.

View Article: PubMed Central - PubMed

Affiliation: Section of Infectious Diseases and Department of Medicine.

ABSTRACT
Posaconazole is the newest azole antifungal approved by the US Food and Drug Administration, and possesses a broad spectrum of activity against numerous yeasts and filamentous fungi. It is available as an oral suspension and is generally well tolerated by patients, but gastrointestinal absorption is sometimes inadequate and remains a clinical concern in treating deep-seated infections. It is used routinely and effectively for the prophylaxis of invasive fungal infections in immunosuppressed hosts and is an effective treatment of oropharyngeal candidiasis, including azole-resistant disease.

No MeSH data available.


Related in: MedlinePlus

Structural formula of posaconazole.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3108746&req=5

f1-idr-3-045: Structural formula of posaconazole.

Mentions: Posaconazole is given orally. The oral solution is administered during or within 20 minutes of a full meal or a liquid nutritional supplement. Alternatively, the drug can be administered with an acidic carbonated drink. It should be stored at 25°C. There is no dose adjustment recommended for renal or liver failure.8,18 The structural formula is shown in Figure 1.


Role of posaconazole in the treatment of oropharyngeal candidiasis.

Ianas V, Matthias KR, Klotz SA - Infect Drug Resist (2010)

Structural formula of posaconazole.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3108746&req=5

f1-idr-3-045: Structural formula of posaconazole.
Mentions: Posaconazole is given orally. The oral solution is administered during or within 20 minutes of a full meal or a liquid nutritional supplement. Alternatively, the drug can be administered with an acidic carbonated drink. It should be stored at 25°C. There is no dose adjustment recommended for renal or liver failure.8,18 The structural formula is shown in Figure 1.

Bottom Line: Posaconazole is the newest azole antifungal approved by the US Food and Drug Administration, and possesses a broad spectrum of activity against numerous yeasts and filamentous fungi.It is available as an oral suspension and is generally well tolerated by patients, but gastrointestinal absorption is sometimes inadequate and remains a clinical concern in treating deep-seated infections.It is used routinely and effectively for the prophylaxis of invasive fungal infections in immunosuppressed hosts and is an effective treatment of oropharyngeal candidiasis, including azole-resistant disease.

View Article: PubMed Central - PubMed

Affiliation: Section of Infectious Diseases and Department of Medicine.

ABSTRACT
Posaconazole is the newest azole antifungal approved by the US Food and Drug Administration, and possesses a broad spectrum of activity against numerous yeasts and filamentous fungi. It is available as an oral suspension and is generally well tolerated by patients, but gastrointestinal absorption is sometimes inadequate and remains a clinical concern in treating deep-seated infections. It is used routinely and effectively for the prophylaxis of invasive fungal infections in immunosuppressed hosts and is an effective treatment of oropharyngeal candidiasis, including azole-resistant disease.

No MeSH data available.


Related in: MedlinePlus